(19)
(11) EP 3 137 453 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.05.2019 Bulletin 2019/20

(45) Mention of the grant of the patent:
27.02.2019 Bulletin 2019/09

(21) Application number: 15721032.9

(22) Date of filing: 01.05.2015
(51) International Patent Classification (IPC): 
C07D 401/06(2006.01)
A61P 31/00(2006.01)
 A61K 31/4439(2006.01)
(86) International application number:
PCT/GB2015/051296
(87) International publication number:
WO 2015/166280 (05.11.2015 Gazette 2015/44)

(54)

POLYMORPHIC FORM OF [5-FLUORO-3-({2-[(4-FLUOROBENZENE) SULFONYL]PYRIDIN-3-YL}METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID

POLYMORPHE FORM EINES [ 5-FLUOR-3-({ 2-[ (4-FLUORBENZOL ) SULFONYL ] PYRIDIN-3-YL } METHYL) -2-METHYLINDOL-1-YL ]-ESSIGSÄURE

FORME POLYMORPHE DE L'ACIDE [5-FLUORO-3-({2-[(4-FLUOROBENZÈNE)SULFONYL]PYRIDIN-3-YL}MÉTHYL)-2-MÉTHYLINDOL-1-YL]-ACÉTIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 02.05.2014 GB 201407820

(43) Date of publication of application:
08.03.2017 Bulletin 2017/10

(73) Proprietor: Chiesi Farmaceutici S.p.A.
43122 Parma (IT)

(72) Inventors:
  • HILFIKER, Rolf
    CH-4303 Kaiseraugst (CH)
  • GROSSE-SENDER, Katja
    CH-4303 Kaiseraugst (CH)

(74) Representative: Cornish, Kristina Victoria Joy et al
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)


(56) References cited: : 
US-A1- 2009 186 923
   
  • CAIRA: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1998, pages 163-208, XP008166276, ISSN: 0340-1022
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).